RecruitingPHASE1, PHASE2NCT06591793
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Studying Usher syndrome type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AAVantgarde Bio Srl
- Intervention
- AAVB-081(biological)
- Enrollment
- 15 enrolled
- Eligibility
- 18-50 years · All sexes
- Timeline
- 2024 – 2029
Study locations (3)
- University of Campania Luigi Vanvitelli, Naples, Italy
- Moorfields Eye Hospital, London, United Kingdom
- Retina Clinic London, London, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06591793 on ClinicalTrials.gov